B7-H3/CD276 Antibody [Unconjugated]

HAF017). A specific band was detected for B7-H3 at approximately 90-110 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." > HAF017). A specific band was detected for B7-H3 at approximately 90-110 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." title="Western blot shows lysates of LNCaP human prostate cancer cell line and U2OS human osteosarcoma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for B7-H3 at approximately 90-110 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." />

Western blot shows lysates of LNCaP human prostate cancer cell line and U2OS human osteosarcoma cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # <a class=

AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107)." > AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107)." title="PC-3 human prostate carcinoma cells were stained with Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027, filled histogram) or control antibody (Catalog # AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107)." />

PC-3 human prostate carcinoma cells were stained with Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027, filled histogram) or control antibody (Catalog # <a class=

CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." > CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." title="B7-H3 was detected in immersion fixed paraffin-embedded sections of human melanoma using Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." />

B7-H3 was detected in immersion fixed paraffin-embedded sections of human melanoma using Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # <a class=

HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." > HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." title="Simple Western lane view shows lysates of U2OS human osteosarcoma cell line, loaded at 0.2 mg/mL. A specific band was detected for B7-H3 at approximately 120-160 kDa (as indicated) using 10 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." />

Simple Western lane view shows lysates of U2OS human osteosarcoma cell line, loaded at 0.2 mg/mL. A specific band was detected for B7-H3 at approximately 120-160 kDa (as indicated) using 10 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # <a class=

HAF017). A specific band was detected for B7-H3 at approximately 95 kDa (as indicated) in the parental U2OS cell line, but is not detectable in knockout U2OS cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." > HAF017). A specific band was detected for B7-H3 at approximately 95 kDa (as indicated) in the parental U2OS cell line, but is not detectable in knockout U2OS cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." title="Western blot shows lysates of U2OS human osteosarcoma parental cell line and B7-H3 knockout U2OS cell line (KO). PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for B7-H3 at approximately 95 kDa (as indicated) in the parental U2OS cell line, but is not detectable in knockout U2OS cell line. GAPDH (Catalog # AF5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." />

Western blot shows lysates of U2OS human osteosarcoma parental cell line and B7-H3 knockout U2OS cell line (KO). PVDF membrane was probed with 1 µg/mL of Goat Anti-Human B7-H3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1027) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # <a class=

CD276 expression in RMS cell lines and PDXs. A CD276 expression levels were evaluated in eleven RMS cell lines, three PDXs, myoblasts, PBMCs, and isolated T cells by WB, revealing high expression in all RMS cell lines, except for the FP-RMS JR and RMS, the FN-RMS Rh18, medium–high levels in the three investigated PDXs, and no detection in the controls. B Surface CD276 expression on eleven RMS cell lines, and myoblasts, PBMCs, and T cells as controls, was assessed by Flow Cytometry confirming high expression of CD276 in all the considered RMS samples, especially in RUCH-3, RD and Rh4, and no detectable expression in the controls. The correspondent isotype controls are shaded in light grey. C The number of CD276 molecules on the surface of RMS cells, PDXs, and controls was estimated by Quantibrite PE beads. D Surface CD276 expression on three RMS PDXs, and PBMCs and T cells, as controls, was assessed by Flow Cytometry confirming high expression of CD276 in all the three PDXs. The correspondent isotype controls are shaded in light grey. E The number of CD276 molecules on the surface of RMS PDXs and controls was estimated by Quantibrite PE beads Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37924157), licensed under a CC-BY license. Not internally tested by R&D Systems.

B7‐H3 is upregulated in cisplatin resistant neuroblastoma cells and regulates neuroblastoma (NB) cell sensitivity to cisplatin. (A) B7‐H3 mRNA expression in SH‐SY5Y/SH‐SY5Y‐R and SK‐N‐SH/SK‐N‐SH‐R NB cells was quantified using qRT‐PCR. (B) B7‐H3 protein expression in SH‐SY5Y/SH‐SY5Y‐R and SK‐N‐SH/SK‐N‐SH‐R NB cells was assessed by western blot. (C) B7‐H3 protein expression in B7‐H3 knockdown SH‐SY5Y‐R and SK‐N‐SH‐R NB cells was determined by western blot. (D,E) Cell Counting Kit‐8 (CCK‐8) assay was conducted to determine the IC50 value of B7‐H3 knockdown SH‐SY5Y‐R and SK‐N‐SH‐R NB cells. **p < 0.01. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/38785199), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of CD276 and FGFR4 on RMS-derived xenografts. A Expression of CD276 was assessed by Flow Cytometry on untreated Rh4-derived xenograft tumors and compared to cultured wild-type Rh4 cells by using a PE-conjugated anti-CD276 antibody. CD276 expression was calculated dividing the geometric mean of antibody-stained cells by the geometric mean of the controls. CD276 expression showed a lower CD276 expression on Rh4 tumor-derived cells, compared to the cultured Rh4 cells. B Expression of FGFR4 was assessed by Flow Cytometry on Rh4-derived xenograft tumors from untreated mice and compared to cultured wild-type Rh4 cells by using a PE-conjugated anti-FGFR4 antibody. FGFR4 expression was calculated dividing the geometric mean of antibody-stained cells by the geometric mean of the isotype controls. The results indicated a strong decrease in FGFR4 expression in Rh4 tumor xenograft-derived cells. C Assessment of CD276 and FGFR4 expression in tumor xenografts tissue by IHC. After treatment, CD276 is still highly detectable on RD- and Rh4-derived tumor xenografts, but low staining detection was observed in JR-derived tumors. FGFR4 seems expressed at low levels on RD, at medium levels on JR, and at high levels on Rh4 Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37924157), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression of CD276 and FGFR4 on RMS-derived xenografts. A Expression of CD276 was assessed by Flow Cytometry on untreated Rh4-derived xenograft tumors and compared to cultured wild-type Rh4 cells by using a PE-conjugated anti-CD276 antibody. CD276 expression was calculated dividing the geometric mean of antibody-stained cells by the geometric mean of the controls. CD276 expression showed a lower CD276 expression on Rh4 tumor-derived cells, compared to the cultured Rh4 cells. B Expression of FGFR4 was assessed by Flow Cytometry on Rh4-derived xenograft tumors from untreated mice and compared to cultured wild-type Rh4 cells by using a PE-conjugated anti-FGFR4 antibody. FGFR4 expression was calculated dividing the geometric mean of antibody-stained cells by the geometric mean of the isotype controls. The results indicated a strong decrease in FGFR4 expression in Rh4 tumor xenograft-derived cells. C Assessment of CD276 and FGFR4 expression in tumor xenografts tissue by IHC. After treatment, CD276 is still highly detectable on RD- and Rh4-derived tumor xenografts, but low staining detection was observed in JR-derived tumors. FGFR4 seems expressed at low levels on RD, at medium levels on JR, and at high levels on Rh4 Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37924157), licensed under a CC-BY license. Not internally tested by R&D Systems.

CD276 expression in RMS cell lines and PDXs. A CD276 expression levels were evaluated in eleven RMS cell lines, three PDXs, myoblasts, PBMCs, and isolated T cells by WB, revealing high expression in all RMS cell lines, except for the FP-RMS JR and RMS, the FN-RMS Rh18, medium–high levels in the three investigated PDXs, and no detection in the controls. B Surface CD276 expression on eleven RMS cell lines, and myoblasts, PBMCs, and T cells as controls, was assessed by Flow Cytometry confirming high expression of CD276 in all the considered RMS samples, especially in RUCH-3, RD and Rh4, and no detectable expression in the controls. The correspondent isotype controls are shaded in light grey. C The number of CD276 molecules on the surface of RMS cells, PDXs, and controls was estimated by Quantibrite PE beads. D Surface CD276 expression on three RMS PDXs, and PBMCs and T cells, as controls, was assessed by Flow Cytometry confirming high expression of CD276 in all the three PDXs. The correspondent isotype controls are shaded in light grey. E The number of CD276 molecules on the surface of RMS PDXs and controls was estimated by Quantibrite PE beads Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37924157), licensed under a CC-BY license. Not internally tested by R&D Systems.

NUTM2A‐AS1 modulates neuroblastoma (NB) cell sensitivity to cisplatin via B7‐H3. (A) NB cells were transfected with si‐NC, si‐NUTM2A‐AS1#1, and Vector‐B7‐H3 and NUTM2A‐AS1 expression was measured by qRT‐PCR assay. (B) Protein expression of B7‐H3 was detected by western blot. (C–F) Cell Counting Kit‐8 (CCK‐8) assay was performed to determine the IC50 value of the indicated SH‐SY5Y‐R and SK‐N‐SH‐R NB cells. *p < 0.05, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/38785199), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, Simple Western, Flow, IHC, CyTOF-ready, KO
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

B7-H3/CD276 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human B7‑H3
  Leu29-Pro245
  Accession # NP_079516
• Specificity: Detects human B7-H3 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CD276
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunohistochemistry 5-15 ug/mL
  • Knockout Validated
  • Simple Western 10 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-H3/CD276 Antibody [Unconjugated]

• B7H3
• B7-H3
• B7H34Ig-B7-H3
• B7-H3B7 homolog 3
• CD276 antigen
• CD276 molecule
• CD276
• Costimulatory molecule

Background

Human B7 homolog 3 (B7-H3) is a member of the B7 family of immune proteins that provide signals for regulating immune responses (1‑3). Other family members include B7-1, B7-2, B7-H2, PD-L1 (B7-H1), and PD-L2. B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and short cytoplasmic domains. Among the family members, they share about 20‑40% amino acid (aa) sequence identity. The cloned human B7-H3 cDNA encodes a 316 aa type I membrane precursor protein with a putative 28 aa signal peptide, a 217 aa extracellular region containing one V-like and one C-like Ig domain, a transmembrane region, and a 45 aa cytoplasmic domain. An isoform of human B7-H3 containing a four-Ig-like domain extracellular region has also been identified. Human B7-H3 is not expressed on resting B cells, T cells, monocytes or dendritic cells, but is induced on dendritic cells and monocytes by inflammatory cytokines. B7-H3 expression is also detected on various normal tissues and in some tumor cell lines. Human B7-H3 does not bind any known members of the CD28 family of immunoreceptors. However, B7-H3 has been shown to bind an unidentified counter-receptor on activated T cells to costimulate the proliferation of CD4⁺ or CD8⁺ T cells. B7-H3 has also been found to enhance the induction of primary cytotoxic T lymphocytes and stimulate IFN-gamma production (1‑3).

1. Chapoval, A.I. et al. (2001) Nat. Immunol. 2:269.
2. Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for B7-H3/CD276 Antibody (AF1027)(41)

Publications using AF1027

• Leo, J;Chen, F;Shi, W;Liang, X;Meng, C;Gu, Q;Albittar, Y;Fan, Z;Zhang, J;Gan, B;Goswami, S;Carmon, K;Frigo, DE;Aparicio, A;Zhao, D; Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis bioRxiv : the preprint server for biology 2026-05-08 [PMID: 42146343] (Human, Xenograft, Immunohistochemistry, Western Blot)
• Seo, YR;Lee, J;Ryu, HS;Kim, EG;Kim, SH;Jeong, J;Jung, H;Jung, Y;Kim, HB;Jo, YH;Kim, YD;Jin, MS;Lee, YY;Kim, KM;Yi, EC; Lateral interactions between CD276 and CD147 are essential for stemness in breast cancer: a novel insight from proximal proteome analysis Scientific reports 2023-08-30 [PMID: 37648771] (IHC, Human)
• Haydar, D;Ibañez-Vega, J;Crawford, J;Chou, CH;Guy, C;Meehl, M;Yi, Z;Langfitt, D;Vogel, P;DeRenzo, C;Gottschalk, S;Roussel, M;Thomas, P;Krenciute, G; CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity Research square 2023-06-06 [PMID: 37333156] (IHC, Mouse)
• Naohito Hashimoto, Tomonari Suzuki, Keisuke Ishizawa, Sumihito Nobusawa, Hideaki Yokoo, Ryo Nishikawa et al. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment Brain Tumor Pathology 2023-07-01 [PMID: 37322295]
• Xiaolei Shi, Abderrahman Day, Hannah E. Bergom, Sydney Tape, Sylvan C. Baca, Zoi E. Sychev et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer npj Precision Oncology 2022-11-02 [PMID: 36323882]
• Stine Asferg Petterson, Mia Dahl Sørensen, Mark Burton, Mads Thomassen, Torben A. Kruse, Signe Regner Michaelsen et al. Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas Brain Pathology 2023-01-01 [PMID: 36093941]
• J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Western Blot, Human)
• Mengli Zhang, Huaichao Zhang, Minjie Fu, Jingwen Zhang, Cheng Zhang, Yingying Lv et al. The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas Frontiers in Cell and Developmental Biology 2021-05-17 [PMID: 34079802]
• R Wang, L Sun, S Xia, H Wu, Y Ma, S Zhan, G Zhang, X Zhang, T Shi, W Chen B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway Cell Death & Disease, 2021-05-06;12(5):453. 2021-05-06 [PMID: 33958586] (IHC, Human)
• Myungeun Lee, Zhi Hong Lu, Charles B. Shoemaker, Jacqueline M. Tremblay, Bradley St. St. Croix, Steven Seaman et al. Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody Journal of Controlled Release 2021-06-01 [PMID: 33872627]
• Theodoros Michelakos, Filippos Kontos, Omar Barakat, Luke Maggs, Joseph H. Schwab, Cristina R. Ferrone et al. B7-H3 targeted antibody-based immunotherapy of malignant diseases Expert Opinion on Biological Therapy 2021-05-04 [PMID: 33301369]
• R Cheng, B Wang, XR Cai, ZS Chen, Q Du, LY Zhou, JM Ye, YL Chen CD276 Promotes Vasculogenic Mimicry Formation in Hepatocellular Carcinoma via the PI3K/AKT/MMPs Pathway Onco Targets Ther, 2020-11-10;13(0):11485-11498. 2020-11-10 [PMID: 33204103] (IHC, Human)
• Y Ma, S Zhan, H Lu, R Wang, Y Xu, G Zhang, L Cao, T Shi, X Zhang, W Chen B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer Cell Death Dis, 2020-10-03;11(10):824. 2020-10-03 [PMID: 33011740] (IHC, Human)
• Meri Sieviläinen, Anna Maria Wirsing, Aini Hyytiäinen, Rabeia Almahmoudi, Priscila Rodrigues, Inger-Heidi Bjerkli et al. Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator Head and Neck Pathology 2021-06-01 [PMID: 32959211] (Immunohistochemistry, Human)
• B Ganesan, S Parameswar, A Sharma, S Krishnakum Clinical relevance of B7H3 expression in retinoblastoma Sci Rep, 2020-06-23;10(1):10185. 2020-06-23 [PMID: 32576886] (IHC, Western Blot, Human)
• Sunitha Bachawal, Gregory R. Bean, Gregor Krings, Katheryne E. Wilson Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression npj Breast Cancer 2020-04-29 [PMID: 32377564] (Immunohistochemistry, Human)
• Huimin Lu, Tongguo Shi, Mingyuan Wang, Xiaomi Li, Yanzheng Gu, Xueguang Zhang et al. B7-H3 inhibits the IFN-gamma -dependent cytotoxicity of V gamma 9Vδ2 T cells against colon cancer cells OncoImmunology 2020-04-14 [PMID: 32363121]
• J Theruvath, E Sotillo, CW Mount, CM Graef, A Delaidelli, S Heitzenede, L Labanieh, S Dhingra, A Leruste, RG Majzner, P Xu, S Mueller, DW Yecies, MA Finetti, D Williamson, PD Johann, M Kool, S Pfister, M Hasselblat, MC Frühwald, O Delattre, D Surdez, F Bourdeaut, S Puget, S Zaidi, SS Mitra, S Cheshier, PH Sorensen, M Monje, CL Mackall Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors Nat. Med., 2020-04-27;26(5):712-719. 2020-04-27 [PMID: 32341579] (IHC, Human)
• Y Ma, R Wang, H Lu, X Li, G Zhang, F Fu, L Cao, S Zhan, Z Wang, Z Deng, T Shi, X Zhang, W Chen B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A J Cancer, 2020-02-03;11(8):2158-2170. 2020-02-03 [PMID: 32127943] (IHC, Western Blot, Human)
• Shenghua Zhan, Zhiju Liu, Min Zhang, Tianwei Guo, Qiuying Quan, Lili Huang et al. Overexpression of B7-H3 in alpha -SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas Frontiers in Oncology 2020-01-10 [PMID: 31998637]
• Ruoqin Wang, Yanchao Ma, Shenghua Zhan, Guangbo Zhang, Lei Cao, Xueguang Zhang et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappa B pathway to induce VEGFA expression Cell Death & Disease 2020-01-23 [PMID: 31974361]
• Dean Nehama, Natalia Di Ianni, Silvia Musio, Hongwei Du, Monica Patané, Bianca Pollo et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres EBioMedicine 2019-09-01 [PMID: 31466914]
• Mischinger, J;Frohlich, E;Mannweiler, S;Meindl, C;Absenger-Novak, M;Hutterer, GC;Seles, M;Augustin, H;Chromecki, TF;Jesche-Chromecki, J;Pummer, K;Zigeuner, R; Prognostic value of B7-H1, B7-H3 and the stage, size, grade and necrosis (SSIGN) score in metastatic clear cell renal cell carcinoma Cent European J Urol 3/14/2019 [PMID: 31011436]
• T Shi, Y Ma, L Cao, S Zhan, Y Xu, F Fu, C Liu, G Zhang, Z Wang, R Wang, H Lu, B Lu, W Chen, X Zhang B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2 Cell Death Dis, 2019-04-05;10(4):308. 2019-04-05 [PMID: 30952834] (IHC-P, Western Blot, Human)
• J Zhang, J Wang, DM Marzese, X Wang, Z Yang, C Li, H Zhang, J Zhang, CC Chen, DF Kelly, W Hua, DSB Hoon, Y Mao B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma Lab. Invest., 2019-03-26;0(0):. 2019-03-26 [PMID: 30914782] (ICC, IHC-P, Western Blot, Human)
• Lei Cai, Theodoros Michelakos, Vikram Deshpande, Kshitij S. Arora, Teppei Yamada, David T. Ting et al. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs) Clinical Cancer Research 2019-04-15 [PMID: 30670493]
• Robbie G. Majzner, Johanna L. Theruvath, Anandani Nellan, Sabine Heitzeneder, Yongzhi Cui, Christopher W. Mount et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors Clinical Cancer Research 2019-04-15 [PMID: 30655315] (FACS, Flow Cytometry, Immunohistochemistry, Human)
• KE Wilson, SV Bachawal, L Abou-Elkac, K Jensen, S Machtaler, L Tian, JK Willmann Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent Theranostics, 2017-04-03;7(6):1463-1476. 2017-04-03 [PMID: 28529630] (IHC, Human)
• D Quandt, E Fiedler, A Müller, WC Marsch, B Seliger High constitutive B7-H3 expression on human keratinocytes supports T cell immunity J. Dermatol. Sci., 2017-04-11;0(0):. 2017-04-11 [PMID: 28465042] (IHC, Human)
• Y Li, G Guo, J Song, Z Cai, J Yang, Z Chen, Y Wang, Y Huang, Q Gao B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway J Cancer, 2017-02-25;8(5):816-824. 2017-02-25 [PMID: 28382144] (IHC-P, Human)
• Chen L, Xie Q, Wang Z et al. Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients. Oncotarget. 11/22/2016 [PMID: 27764786]
• Sangbin Lim, Hao Liu, Luciana Madeira Madeira da Silva, Ritu Arora, Zixing Liu, Joshua B. Phillips et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF-1 alpha Cancer Research 2016-04-15 [PMID: 27197253]
• BR Yoon, YH Chung, SJ Yoo, K Kawara, J Kim, IS Yoo, CG Park, SW Kang, WW Lee Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis J. Biol. Chem, 2015-12-23;291(8):4048-57. 2015-12-23 [PMID: 26702052] (Western Blot, Human)
• SHAN-SHAN ZHANG, JING TANG, SHU-YI YU, L I MA, FENG WANG, SHU-LE XIE et al. Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma Oncology Letters 2015-08-01 [PMID: 26622626]
• Bachawal S, Jensen K, Wilson K, Tian L, Lutz A, Willmann J Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging. Cancer Res, 2015-04-21;75(12):2501-9. 2015-04-21 [PMID: 25899053] (IHC-P, Human)
• Sun J, Fu F, Gu W, Yan R, Zhang G, Shen Z, Zhou Y, Wang H, Shen B, Zhang X Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system. PLoS ONE, 2011-09-13;6(9):e24751. 2011-09-13 [PMID: 21931843] (Western Blot, Human)
• Nagai Y, Aso H, Ogasawara H, Tanaka S, Taketa Y, Watanabe K, Ohwada S, Rose MT, Kitazawa H, Yamaguchi T Anterior pituitary progenitor cells express costimulatory molecule 4Ig-B7-H3. J. Immunol., 2008-11-01;181(9):6073-81. 2008-11-01 [PMID: 18941196] (Western Blot, Bovine)
• Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res., 2008;14(16):5150-7. 2008 [PMID: 18694993] (IHC Paraffin-embedded, Human)
• Tran CN, Thacker SG, Louie DM, Oliver J, White PT, Endres JL, Urquhart AG, Chung KC, Fox DA Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3. J. Immunol., 2008-03-01;180(5):2989-98. 2008-03-01 [PMID: 18292521] (ICC, IHC-Fr, IHC-P, Human)
• Jang BC, Park YK, Choi IH, Kim SP, Hwang JB, Baek WK, Suh MH, Mun KC, Suh SI 12-O-tetradecanoyl phorbol 13-acetate induces the expression of B7-DC, -H1, -H2, and -H3 in K562 cells. Int. J. Oncol., 2007-12-01;31(6):1439-47. 2007-12-01 [PMID: 17982670] (Flow Cytometry, Human)
• Petroff MG, Kharatyan E, Torry DS, Holets L The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am. J. Pathol., 2005-08-01;167(2):465-73. 2005-08-01 [PMID: 16049332] (IHC-P, Western Blot, Human)

Review for B7-H3/CD276 Antibody (AF1027) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer IHC-Fr Human 01/05/2015

Summary

• Application: Immunohistochemistry-Frozen
• Sample Tested: See PMID 22080438
• Species: Human

Bioinformatics

• Gene Symbol: CD276
• Uniprot:
  • NP_079516()